Description
FAUC 213 is an orally active and highly selective dopamine D4 receptor complete antagonist with a Ki of 2.2 nM for hD4.4. FAUC 213 has less activity on D2 and D3 receptors (Kis of 3.4 μM, 5.3 μM for hD2, hD3, respectively). FAUC 213 can cross the blood-brain barrier (BBB). FAUC 213 exhibits atypical antipsychotic characteristic.
Product information
CAS Number: 337972-47-1
Molecular Weight: 326.82
Formula: C18H19ClN4
Chemical Name: 1-(4-chlorophenyl)-4-({pyrazolo[1,5-a]pyridin-2-yl}methyl)piperazine
Smiles: ClC1C=CC(=CC=1)N1CCN(CC2C=C3C=CC=CN3N=2)CC1
InChiKey: DTRXURJDKOYCCD-UHFFFAOYSA-N
InChi: InChI=1S/C18H19ClN4/c19-15-4-6-17(7-5-15)22-11-9-21(10-12-22)14-16-13-18-3-1-2-8-23(18)20-16/h1-8,13H,9-12,14H2
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vitro:
FAUC 213 inhibits p5-HT1 (Ki=1.2 μM)，p5-HT2 (Ki=0.52 μM)，pα1 (Ki=0.27 μM).
In Vivo:
FAUC 213 (7.5-30 mg/kg; orally; single dose) significantly reduces this elevation in AMPH-induced locomotor hyper-activity only pre-treatment with 30 mg/kg. FAUC 213 significantly restores the prepulse inhibition (PPI) reduction caused by the apomorphine (APO) treatment with 30 mg/kg.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.